Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone

Current Medical Research and Opinion

Volumn 19, Issue 4, 2003, Pages 298-305

  Martin, Stephen D ^a   Libretto, Susan E ^b   Pratt, David J ^c   Brewin, J S ^d   Huq, Zahid ul ^e   Saleh, B T ^f  

^a UNIVERSITY OF SUNDERLAND   (United Kingdom)

^b Janssen Cilag Ltd   (United Kingdom)

^c TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^f SCUNTHORPE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Antipsychotics; Efficacy; Relapse; Risperidone; Safety; Schizophrenia

Indexed keywords

AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; FLUPENTIXOL; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LONG ACTING DRUG; MEDISORB; MICROSPHERE; NEUROLEPTIC AGENT; PROCYCLIDINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANXIETY; ARTICLE; CASE REPORT; CHOREOATHETOSIS; CLINICAL FEATURE; CONFUSION; DEPRESSION; DISEASE SEVERITY; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HIGH RISK PATIENT; HUMAN; INJECTION; INJECTION PAIN; MALE; MEDICAL DECISION MAKING; MUSCLE RIGIDITY; OUTCOMES RESEARCH; PARKINSONISM; PATIENT COMPLIANCE; RATING SCALE; RELAPSE; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SOCIAL INTERACTION; SYMPTOM; TARDIVE DYSKINESIA; TREMOR; WORK RESUMPTION;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0038343116     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125001893     Document Type: Article

References (26)

1. Gerlach J. Depot neuroleptics in relapse prevention. I. Advantages and disadvantages. ICP 1995;55:17-20
2. Kane JM, Aguglia, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55-66
3. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995;52:173-88
4. Mann JJ. How medication compliance affects outcome. Psychiatr Ann 1986;16:567-70
5. Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
6. Geddes J. Prevention of relapse in schizophrenia. N Engl J Med 2002;346:56-8
7. Davis JM, Matalon L, Wananabe MD, et al. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741-73
8. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analyses: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46
9. Kane JM, Eerdekens M, Keith SJ, et al. Efficacy and safety of a novel long-acting risperidone microspheres formulation. Schizophrenia Res 2002;53(Suppl):174 (Abstr B63)
10. Eerdekens M, Fleischhacker WW, Xie Y, et al. Long-term safety of long-acting risperidone microspheres. Schizophrenia Res 2002;53(Suppl):174 (Abstr B64)
11. Chue P, Eerdekens M, Augustyns I, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Schizophrenia Res 2002;53(Suppl):174-5 (Abstr B65)
12. Summary of Manufacturer's Product Characteristics for Risperdal Consta™.
13. Kay SR, Fiszbein A, Opler LA. The positive-negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 1987;13:261-76
14. US Department of Health EaW. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338 ed. Washington DC: US Department of Health, Education and Welfare, 1976
15. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233
16. Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: Do they hurt? J Clin Psychiatry 2001;62:855-9
17. Hamann GL, Egan TM, Wells BG, et al. Injections site reactions after intramuscular administration of haloperidol decanoate 100 mg/ml. J Clin Psychiatry 1990;51:502-4
18. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-7
19. Hagström P, Hansson B-M. Practical handling aspects of long-lasting risperidone microspheres (Risperdal Consta): an attitude survey. Nord J Psychiatry 2002;56:18
20. Quartermaine S, Taylor R. A comparative study of depot injection techniques. Nurs Times 1995;91:36-9
21. Dworkin RH. Pain sensitivity in schizophrenia: a neglected phenomenon and some implications. Schizophrenia Bull 1994;20:235-48
22. Guieu R, Samuelian JC, Coulouvrant H. Objective evaluation of pain perception in patients with schizophrenia. Br J Psychiatry 1994;164:253-5
23. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000;17:383-9
24. Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 1985;46:18-21
25. Chue PS, Devos E, Duchesne IY, et al. One year hospitalization rates in patients with schizophrenia during long-term treatment with long-acting risperidone. Value in Health 2002;5:229
26. Llorca P-M, Devos E, Eerdekens M, et al. Rehospitalisation rates with long-acting risperidone injection are lower than those reported for other antipsychotics. Poster presentation at the XXIII CINP Congress, Montreal, Canada, June 23-27, 2002